Early electroretinografic changes in elderly RA patients treated with hydroxychloroquine;Variazioni elettroretinografiche precoci nei pazienti anziani con artrite reumatoide trattata con idrossiclorochina

Reumatismo

Volumn 54, Issue 3, 2002, Pages 226-231

  Cavagna, L ^a   Rossi, P ^a   Bogliolo, L ^a   Antoniazzi, E ^a   Gelmi, C ^a   Caporali, R ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Electroretinogram; Hydroxychloroquine; Retinal toxicity; Rheumatoid arthritis

Indexed keywords

HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; NIGHT VISION; OPHTHALMOSCOPY; PHOTOPIC VISION; RETINOPATHY; RHEUMATOID ARTHRITIS;

ADULT; AGE FACTORS; AGED; ARTHRITIS, RHEUMATOID; ELECTROOCULOGRAPHY; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; OPHTHALMOSCOPES; PREDICTIVE VALUE OF TESTS; RETINA; RETINAL DISEASES;

EID: 0036390794     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Khraishi MM, Singh G. The role of anti-malarials in rheumatoid arthritis - the American experience. Lupus 1996; 5: S41-4.
2. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: S80-5.
3. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799-805.
4. The HERA study group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis. The HERA study. Am J Med 1995; 98: 156-68.
5. Caporali R, Belfiore N, Rossi S, Comaschi E, Epis O, Montecucco C. Combination therapy with cyclosporin A, methotrexate and hydroxychloroquine in severe, refractory rheumatoid arthritis: a pilot study. Haematologica 1998; 83: 70-1.
6. O'Dell JR. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate. Clin Exp Rheumatol 1999; 17: 53-8.
7. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55: 187-9.
8. Levy GD, Munz SJ, Paschal J,HB Cohen, KJ Pince, T Peterson. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large, multicenter outpatient pratice. Arthritis Rheum 1997; 40: 1482-6.
9. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophtalmol 1993; 25: 385-8.
10. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997; 56: 188-90.
11. May K, Metcalf T, Gough A. Screening for hydroxychloroquine retinopathy. BMJ 1998; 317: 1388-9.
12. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112: 528-34.
13. Rynes RI. Opthalmologic considerations in using antimalarials in the United States. Lupus 1996; 5: 73-4.
14. Easterbrook M. Detection and prevention of maculopathy associated with antimalanal agents. Int Ophthalmol Clin 1999; 39: 49-57.
15. Spalton DJ. Retinopathy and antimalarial drugs: the British experience. Lupus 1996; 5: 70-2.
16. Bishara SA, Matamoros N. Evaluation of several tests in screening for chloroqume maculopathy. Eye. 1989; 3: 777-82.
17. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997; 36: 599-01.
18. Rigaudiere F, Pizzato M, Albuisson E, Le Gargasson JF, Grall Y. Statistical results of 700 electrophysiologic tests (ERG) in patients without with I out ophthalmologic manifestations treated with synthetic antimalarials for rheumatologic or dermatologic disease. Ophtalmologie 1990; 4: 254-9.
19. Easterbrook M. The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Ophthalmol Soc UK 1985; 104: 204-7.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. Bach M, Hawlina M, Holder GE, Marmor MF, Meigen T, Vaegan, et al. Standard for pattern electroretinography. International Society for Clinical Electrophysiology of Vision. Doc Ophthalmol. 2000; 101: 11-8.
22. Marmor MF, Zrenner E. Standard for clinical electrooculography. Arch Ophthalmol 1993; 111: 601-4.
23. rd ed, New York: Lippincott-Raven Press, 1997.
24. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 3-7.
25. Maksymowych W, Russel AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206-21.
26. Pinckers A, Broekhuyse RM. The EOG in rheumatoid arthritis. Acta Ophthalmol 1983; 61: 831-7.
27. Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967; 12: 415-47.
28. Francois P, Constantinides G, Turut P, Hache JC. Signs of retinal lesion necessitating the cessation of synthetic antimalarials. Bull Med Soc Fr Ophtalmol 1973; 86: 158-63.
29. Douche C, Bechetoille A, Ebran JM. Routine monitoring of patients treated with synthetic antimalarials. J Fr Ophtalmol 1983; 6: 689-95.
30. Zahan JR, Brinton GF, Norton E. Ocular quinine toxicity followed by electroretinogram, elettro-oculogram and pattern visually evoked potential. Am J Optom Physiol Opt 1981; 58: 492-8.
31. Bass SJ, Sherman J, Bodis-Wollner I, Nath S. Visual evoked potential in macular disease. Invest Ophthalmol Vis Sci 1985; 26: 1071-4.